Jagmohan Hooda

Senior Research Project Director

University of Pittsburgh
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Year:

2026

S1. FOXA1 redistribution in ESR1 mutant cells causes distinct ER-FOXA1 interaction.S2. FOXA1 gained peaks annotated genes are significantly associated with novel target genes.S3. FOXA1 redistribution in ESR1 mutant cells confers potential RXR binding sites.S4. RXR agonist LG100268 can promote colonization and growth of ESR1 mutant cells.S5. Clonogenic survival assay and 2D growth assay to test RXR response in Park and Gertz MCF7 cell models.S6. FOXA1 knockdown drastically attenuated the base line growth of both ESR1 WT and mutant cells.S7. RXR antagonist HX531 can inhibit the response of ESR1 mutant cells to RXR agonist.S8. RXR antagonist HX531 can inhibit the basal and agonist promoted growth of IPM-PDXO-073 organoid.

Year:

2025

Breast cancer is a heterogeneous disease with numerous histological subtypes. Invasive lobular cancer (ILC) is the most common special subtype, accounting for 10-15% of all breast cancers. The pathognomonic feature of ILC is the loss of E-cadherin (CDH1), which leads to a unique single-file growth pattern of discohesive cells. Although ILCs show better prognostic factors than the most common No Special Type (NST) of breast cancer, patients with ILC have worse long-term outcomes, which is not well understood. In this study, we aimed to identify and characterize Patient-Derived Xenograft (PDX) models of ILC based upon the presence of truncating CDH1 mutations and/or low CDH1 mRNA expression among 128 human breast cancer PDX models. We selected 8 PDX models for validation using Immunohistochemical (IHC) analysis for E-Cadherin, p120, ER, PR, and HER2. We confirmed that seven of these PDX models are indeed ILC while one was identified as mixed NST-ILC PDX. Molecular analysis of the confirmed ILC PDX models showed enrichment of truncating CDH1 mutations, significantly lower levels of CDH1 mRNA expression and predominantly luminal subtypes compared to NST PDX models, in line with the molecular characteristics of human ILC disease. The commonly altered genes in the ILC PDX models included PIK3CA (57%), CDH1 (57%) and TP53 (57%) among others. Our study confirms and characterizes new ILC PDX models, offering valuable tools to advance our understanding of human ILC biology and support the development of innovative treatment strategies.

Year:

2025

Breast cancer is a leading cause of female mortality and despite advancements in personalized therapeutics, metastatic disease largely remains incurable due to drug resistance. The estrogen receptor (ER, ESR1) is expressed in two-thirds of all breast cancer, and under endocrine stress, somatic ESR1 mutations arise in approximately 30% of cases that result in endocrine resistance. We and others reported ESR1 fusions as a mechanism of ER-mediated endocrine resistance. ER fusions, which retain the activation function 1- and DNA-binding domains, harbor ESR1 exons 1 to 6 fused to an in-frame gene partner resulting in loss of the ER ligand-binding domain (LBD). We demonstrate that in a no-special type (invasive ductal carcinoma [IDC]-NST) and an invasive lobular carcinoma (ILC) cell line, ER fusions exhibit robust hyperactivation of canonical ER signaling pathways independent of estradiol or antiendocrine therapies. We employ cell line models stably overexpressing ER fusions with concurrent endogenous ER knockdown to minimize endogenous ER influence. Cell lines exhibited shared transcriptomic enrichment in pathways known to be drivers of metastatic disease, notably MYC signaling. Cells expressing the 3′ fusion partners SOX9 and YAP1 consistently demonstrated enhanced growth and cell survival. ILC cells expressing the DAB2 fusion led to enhanced growth, survival, and migration, phenotypes not appreciated in the IDC-NST DAB2 model. Herein, we report that cell line activity is subtype-, fusion-, and assay-specific, suggesting that LBD loss, the fusion partner, and the cellular landscape all influence fusion activities. Therefore, it will be critical to assess fusion frequency in the context of the clinicopathology.

Year:

2024

Estrogen receptor alpha (ER/ESR1) mutations occur in 30-40% of endocrine resistant ER-positive (ER+) breast cancer. Forkhead Box A1 (FOXA1) is a key pioneer factor mediating ER-chromatin interactions and endocrine response in ER+ breast cancer, but its role in ESR1 mutant breast cancer remains unclear. Our previous FOXA1 ChIP-seq identified a large portion of redistributed binding sites in T47D genome-edited Y537S and D538G ESR1 mutant cells. Here, we further integrated FOXA1 genomic binding profile with the isogenic ER cistrome, accessible genome and transcriptome data of T47D cell model. FOXA1 redistribution was significantly associated with transcriptomic alterations caused by ESR1 mutations. Furthermore, in ESR1 mutant cells, FOXA1 binding sites less frequently overlapped with ER, and differential gene expression was less associated with the canonical FOXA1-ER axis. Motif analysis revealed a unique enrichment of retinoid X receptor (RXR) motifs in FOXA1 binding sites of ESR1 mutant cells. Consistently, ESR1 mutant cells were more sensitive to growth stimulation with the RXR agonist LG268. The mutant-specific response was dependent on two RXR isoforms, RXR-α and RXR-β, with a stronger dependency on the latter. In addition, T3, the agonist of thyroid receptor also showed a similar growth-promoting effect in ESR1 mutant cells. Importantly, RXR antagonist HX531 blocked growth of ESR1 mutant cells and a patient derived xenograft (PDX)-derived organoid with an ESR1 D538G mutation. Collectively, our data support evidence for a stronger RXR response associated with FOXA1 reprogramming in ESR1 mutant cells, suggesting development of therapeutic strategies targeting RXR pathways in breast tumors with ESR1 mutation. Implications: It provides comprehensive characterization of the role of FOXA1 in ESR1 mutant breast cancer and potential therapeutic strategy through blocking RXR activation.

Year:

2024

S1. FOXA1 redistribution in ESR1 mutant cells causes distinct ER-FOXA1 interaction. S2. FOXA1 gained peaks annotated genes are significantly associated with novel target genes. S3. FOXA1 redistribution in ESR1 mutant cells confers potential RXR binding sites. S4. RXR agonist LG100268 can promote colonization and growth of ESR1 mutant cells. S5. Clonogenic survival assay and 2D growth assay to test RXR response in Park and Gertz MCF7 cell models. S6. FOXA1 knockdown drastically attenuated the base line growth of both ESR1 WT and mutant cells. S7. RXR antagonist HX531 can inhibit the response of ESR1 mutant cells to RXR agonist. S8. RXR antagonist HX531 can inhibit the basal and agonist promoted growth of IPM-PDXO-073 organoid.

Year:

2024

S1. FOXA1 redistribution in ESR1 mutant cells causes distinct ER-FOXA1 interaction. S2. FOXA1 gained peaks annotated genes are significantly associated with novel target genes. S3. FOXA1 redistribution in ESR1 mutant cells confers potential RXR binding sites. S4. RXR agonist LG100268 can promote colonization and growth of ESR1 mutant cells. S5. Clonogenic survival assay and 2D growth assay to test RXR response in Park and Gertz MCF7 cell models. S6. FOXA1 knockdown drastically attenuated the base line growth of both ESR1 WT and mutant cells. S7. RXR antagonist HX531 can inhibit the response of ESR1 mutant cells to RXR agonist. S8. RXR antagonist HX531 can inhibit the basal and agonist promoted growth of IPM-PDXO-073 organoid.

Year:

2024

Year:

2023

Collaborators (9)

Jason Carroll

Professor of Molecular Oncology

University of Cambridge

UNITED KINGDOM
View details

Osama Shiraz Shah

University of Nebraska Medical Center

UNITED STATES
View details

Jennifer Xavier

University of Pittsburgh

UNITED STATES
View details

Adrian V. Lee

University of Pittsburgh

UNITED STATES
View details

Steffi Oesterreich

UPMC Hillman Cancer Center

UNITED STATES
View details

Jason Gertz

Professor

University of Utah School of Medicine

UNITED STATES
View details

Daniel D Brown

Senior Research Scientist

University of Pittsburgh

UNITED STATES
View details

Shalini Rao

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Soleilmane Omarjee

Université Claude Bernard Lyon 1 - Domaine de Rockefeller

FRANCE
View details